 | Up a level |
Journal Article
Buisseret, L., Loirat, D., Aftimos, P. G., Punie, K., Maurer, C., Debien, V., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., van den Mooter, T. F. A., Ferrero, J-M., Bonnefoi, H., Canon, J-L., Duhoux, F. P., Bazan, F., Kristanto, P., de Azambuja, E., Ignatiadis, M. and Piccart, M. (2022). Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC). Ann. Oncol., 33 (7). S. S1385 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Eiger, D., Maurer, C., Brandao, M., Aftimos, P. G., Punie, K., Taylor, D., Van den Mooter, T., Poncin, R., Canon, J-L., Duhoux, F., Casert, V., Clatot, F., Velghe, C., Craciun, L., Paesmans, M., de Azambuja, E., Ignatiadis, M., Larsimont, D., Piccart, M. and Buisseret, L. (2020). First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC). Ann. Oncol., 31. S. S386 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041